The Clinical Utility of Salivary Biomarkers in the Identification of Type 2 Diabetes Risk and Metabolic Syndrome

References

• American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl1):S13–S27. doi:10.2337/dc18-S002.
   PubMedGoogle Scholar
• Mitrakou A, Kelley D, Mokan M, et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med. 1992;326(1):22–29. doi:10.1056/NEJM199201023260104
   PubMed Web of Science ®Google Scholar
• Defronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–795. doi:10.2337/db09-9028
   PubMed Web of Science ®Google Scholar
• Hannon TS, Arslanian SA. The changing face of diabetes in youth: lessons learned from studies of type 2 diabetes. Ann N Y Acad Sci. 2015;1353:113–137. doi:10.1111/nyas.12939
   PubMed Web of Science ®Google Scholar
• Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001;345(11):790–797. doi:10.1056/NEJMoa010492
   PubMed Web of Science ®Google Scholar
• Weber MB, Narayan KMV. Health insurance for diabetes prevention confers health benefits and breaks even on cost within 2 years. Diabetes Care. 2019;42(9):1612–1614. doi:10.2337/dci19-0022
   PubMedGoogle Scholar
• Abrahamian H, Endler G, Exner M, et al. Association of low-grade inflammation with nephropathy in type 2 diabetic patients: role of elevated CRP-levels and 2 different gene-polymorphisms of proinflammatory cytokines. Exp Clin Endocrinol Diabetes. 2007;115(1):38–41. doi:10.1055/s-2007-948213
   PubMedGoogle Scholar
• Randeria SN, Thomson GJA, Nell TA, Roberts T, Pretorius E. Inflammatory cytokines in type 2 diabetes mellitus as facilitators of hypercoagulation and abnormal clot formation. Cardiovasc Diabetol. 2019;18(1):72. doi:10.1186/s12933-019-0870-9
   PubMedGoogle Scholar
• Spranger J, Kroke A, Mohlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-potsdam study. Diabetes. 2003;52(3):812–817. doi:10.2337/diabetes.52.3.812
   PubMed Web of Science ®Google Scholar
• Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157:107843. doi:10.1016/j.diabres.2019.107843
   PubMed Web of Science ®Google Scholar
• Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–1053. doi:10.2337/diacare.27.5.1047
   PubMed Web of Science ®Google Scholar
• Rowley WR, Bezold C, Arikan Y, Byrne E, Krohe S. Diabetes 2030: insights from yesterday, today, and future trends. Popul Health Manag. 2017;20(1):6–12. doi:10.1089/pop.2015.0181
   PubMed Web of Science ®Google Scholar
• Tabish SA. Is diabetes becoming the biggest epidemic of the twenty-first century? Int J Health Sci (Qassim). 2007;1(2):V–VIII.
   PubMedGoogle Scholar
• Wu Y, Ding Y, Tanaka Y, Zhang W. Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention. Int J Med Sci. 2014;11(11):1185–1200. doi:10.7150/ijms.10001
   PubMed Web of Science ®Google Scholar
• Nadeau KJ, Anderson BJ, Berg EG, et al. Youth-onset type 2 diabetes consensus report: current status, challenges, and priorities. Diabetes Care. 2016;39(9):1635–1642. doi:10.2337/dc16-1066
   PubMed Web of Science ®Google Scholar
• Dall TM, Yang W, Gillespie K, et al. The economic burden of elevated blood glucose levels in 2017: diagnosed and undiagnosed diabetes, gestational diabetes mellitus, and prediabetes. Diabetes Care. 2019;42(9):1661–1668. doi:10.2337/dc18-1226
   PubMed Web of Science ®Google Scholar
• Huang T, Glass K, Zeleznik OA, et al. A network analysis of biomarkers for type 2 diabetes. Diabetes. 2019;68(2):281–290. doi:10.2337/db18-0892
   PubMedGoogle Scholar
• Abbasi A, Stolk RP, Bakker SJ. Identification of relevant biomarkers for type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2(2):106–107. doi:10.1016/S2213-8587(14)70005-1
   PubMedGoogle Scholar
• Ahluwalia TS, Kilpelainen TO, Singh S, Rossing P. Editorial: novel biomarkers for type 2 diabetes. Front Endocrinol (Lausanne). 2019;10:649. doi:10.3389/fendo.2019.00649
   PubMedGoogle Scholar
• Dorcely B, Katz K, Jagannathan R, et al. Novel biomarkers for prediabetes, diabetes, and associated complications. Diabetes Metab Syndr Obes. 2017;10:345–361. doi:10.2147/DMSO.S100074
   PubMedGoogle Scholar
• Yoshizawa JM, Schafer CA, Schafer JJ, Farrell JJ, Paster BJ, Wong DT. Salivary biomarkers: toward future clinical and diagnostic utilities. Clin Microbiol Rev. 2013;26(4):781–791. doi:10.1128/CMR.00021-13
   PubMed Web of Science ®Google Scholar
• Carpenter GH. The secretion, components, and properties of saliva. Annu Rev Food Sci Technol. 2013;4:267–276. doi:10.1146/annurev-food-030212-182700
   PubMed Web of Science ®Google Scholar
• Nunes LA, Mussavira S, Bindhu OS. Clinical and diagnostic utility of saliva as a non-invasive diagnostic fluid: a systematic review. Biochem Med (Zagreb). 2015;25(2):177–192. doi:10.11613/BM.2015.018
   PubMed Web of Science ®Google Scholar
• Dawes C. Considerations in the development of diagnostic tests on saliva. Ann N Y Acad Sci. 1993;694:265–269. doi:10.1111/j.1749-6632.1993.tb18359.x
   PubMedGoogle Scholar
• Yeh CK, Christodoulides NJ, Floriano PN, et al. Current development of saliva/oral fluid-based diagnostics. Tex Dent J. 2010;127(7):651–661.
   PubMedGoogle Scholar
• Tiwari M. Science behind human saliva. J Nat Sci Biol Med. 2011;2(1):53–58. doi:10.4103/0976-9668.82322
   PubMedGoogle Scholar
• Thanakun S, Watanabe H, Thaweboon S, Izumi Y. Comparison of salivary and plasma adiponectin and leptin in patients with metabolic syndrome. Diabetol Metab Syndr. 2014;6(1):19. doi:10.1186/1758-5996-6-19
   PubMedGoogle Scholar
• Mamali I, Roupas ND, Armeni AK, Theodoropoulou A, Markou KB, Georgopoulos NA. Measurement of salivary resistin, visfatin and adiponectin levels. Peptides. 2012;33(1):120–124. doi:10.1016/j.peptides.2011.11.007
   PubMed Web of Science ®Google Scholar
• Tvarijonaviciute A, Castillo C, Ceron JJ, Martinez-Subiela S, Tecles F, Lopez-Jornet P. Leptin and NGF in saliva of patients with diabetes mellitus type 2: a pilot study. J Oral Pathol Med. 2017;46(9):853–855. doi:10.1111/jop.12587
   PubMed Web of Science ®Google Scholar
• Costa PP, Trevisan GL, Macedo GO, et al. Salivary interleukin-6, matrix metalloproteinase-8, and osteoprotegerin in patients with periodontitis and diabetes. J Periodontol. 2010;81(3):384–391. doi:10.1902/jop.2009.090510
   PubMed Web of Science ®Google Scholar
• Monea A, Gruber R, Elod N, Beresescu G, Moldovan C, Monea M. Saliva and serum levels of tnf-[alpha] and il-6 in a sample of romanian adult subjects with type 2 diabetes mellitus and periodontal disease. Eur Sci J. 2014;10:9.
   Google Scholar
• Gao X, Jiang S, Koh D, Hsu CY. Salivary biomarkers for dental caries. Periodontol 2000. 2016;70(1):128–141. doi:10.1111/prd.12100
   PubMed Web of Science ®Google Scholar
• Phillips SA, Ciaraldi TP, Kong AP, et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes. 2003;52(3):667–674. doi:10.2337/diabetes.52.3.667
   PubMed Web of Science ®Google Scholar
• Siitonen N, Pulkkinen L, Lindstrom J, et al. Association of ADIPOQ gene variants with body weight, type 2 diabetes and serum adiponectin concentrations: the Finnish Diabetes Prevention Study. BMC Med Genet. 2011;12:5. doi:10.1186/1471-2350-12-5
   PubMed Web of Science ®Google Scholar
• Ryo M, Nakamura T, Kihara S, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J. 2004;68(11):975–981. doi:10.1253/circj.68.975
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7(8):941–946. doi:10.1038/90984
   PubMed Web of Science ®Google Scholar
• Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257(1):79–83. doi:10.1006/bbrc.1999.0255
   PubMed Web of Science ®Google Scholar
• Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20(6):1595–1599. doi:10.1161/01.atv.20.6.1595
   PubMed Web of Science ®Google Scholar
• Yoon MJ, Lee GY, Chung JJ, Ahn YH, Hong SH, Kim JB. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha. Diabetes. 2006;55(9):2562–2570. doi:10.2337/db05-1322
   PubMed Web of Science ®Google Scholar
• Cheng KK, Lam KS, Wang Y, et al. Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells. Diabetes. 2007;56(5):1387–1394. doi:10.2337/db06-1580
   PubMed Web of Science ®Google Scholar
• Gariballa S, Alkaabi J, Yasin J, Al Essa A. Total adiponectin in overweight and obese subjects and its response to visceral fat loss. BMC Endocr Disord. 2019;19(1):55. doi:10.1186/s12902-019-0386-z
   PubMedGoogle Scholar
• Altinova AE, Toruner F, Bukan N, et al. Decreased plasma adiponectin is associated with insulin resistance and HDL cholesterol in overweight subjects. Endocr J. 2007;54(2):221–226. doi:10.1507/endocrj.k06-021
   PubMedGoogle Scholar
• Santaniemi M, Kesaniemi YA, Ukkola O. Low plasma adiponectin concentration is an indicator of the metabolic syndrome. Eur J Endocrinol. 2006;155(5):745–750. doi:10.1530/eje.1.02287
   PubMed Web of Science ®Google Scholar
• Gannage-Yared MH, Khalife S, Semaan M, Fares F, Jambart S, Halaby G. Serum adiponectin and leptin levels in relation to the metabolic syndrome, androgenic profile and somatotropic axis in healthy non-diabetic elderly men. Eur J Endocrinol. 2006;155(1):167–176. doi:10.1530/eje.1.02175
   PubMedGoogle Scholar
• Iwata M, Hara K, Kamura Y, et al. Ratio of low molecular weight serum adiponectin to the total adiponectin value is associated with type 2 diabetes through its relation to increasing insulin resistance. PLoS One. 2018;13(3):e0192609. doi:10.1371/journal.pone.0192609
   PubMed Web of Science ®Google Scholar
• Wang LH, Liu YC, Hou JS, Wu DA, Hsu BG. Hypoadiponectemia is associated with metabolic syndrome in patients with type 2 diabetes. Int J Clin Exp Pathol. 2017;10(10):10515–10521.
   PubMedGoogle Scholar
• Goodson JM, Kantarci A, Hartman ML, et al. Metabolic disease risk in children by salivary biomarker analysis. PLoS One. 2014;9(6):e98799. doi:10.1371/journal.pone.0192609
   PubMedGoogle Scholar
• Harris RB. Leptin–much more than a satiety signal. Annu Rev Nutr. 2000;20:45–75. doi:10.1146/annurev.nutr.20.1.45
   PubMed Web of Science ®Google Scholar
• Yadav A, Kataria MA, Saini V, Yadav A. Role of leptin and adiponectin in insulin resistance. Clin Chim Acta. 2013;417:80–84. doi:10.1016/j.cca.2012.12.007
   PubMed Web of Science ®Google Scholar
• Yang R, Barouch LA. Leptin signaling and obesity: cardiovascular consequences. Circ Res. 2007;101(6):545–559. doi:10.1161/CIRCRESAHA.107.156596
   PubMed Web of Science ®Google Scholar
• Serradeil-le Gal C, Raufaste D, Brossard G, et al. Characterization and localization of leptin receptors in the rat kidney. FEBS Lett. 1997;404(2–3):185–191. doi:10.1016/s0014-5793(97)00125-7
   PubMedGoogle Scholar
• Liu W, Zhou X, Li Y, et al. Serum leptin, resistin, and adiponectin levels in obese and non-obese patients with newly diagnosed type 2 diabetes mellitus: a population-based study. Medicine (Baltimore). 2020;99(6):e19052. doi:10.1097/MD.0000000000019052
   PubMed Web of Science ®Google Scholar
• Schmidt MI, Duncan BB, Vigo A, et al. Leptin and incident type 2 diabetes: risk or protection? Diabetologia. 2006;49(9):2086–2096. doi:10.1007/s00125-006-0351-z
   PubMed Web of Science ®Google Scholar
• Esteghamati A, Khalilzadeh O, Anvari M, Rashidi A, Mokhtari M, Nakhjavani M. Association of serum leptin levels with homeostasis model assessment-estimated insulin resistance and metabolic syndrome: the key role of central obesity. Metab Syndr Relat Disord. 2009;7(5):447–452. doi:10.1089/met.2008.0100
   PubMedGoogle Scholar
• Lee SW, Jo HH, Kim MR, You YO, Kim JH. Association between metabolic syndrome and serum leptin levels in postmenopausal women. J Obstet Gynaecol. 2012;32(1):73–77. doi:10.3109/01443615.2011.618893
   PubMedGoogle Scholar
• Zulfania KA, Ghaffar T, Kainat A, Arabdin M, Rehman Orakzai SU. Correlation between serum leptin level and body mass index (BMI) in patients with type 2 diabetes mellitus. J Pak Med Assoc. 2020;70(1):3–6. doi:10.5455/JPMA.301135
   PubMedGoogle Scholar
• Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334(5):292–295. doi:10.1056/NEJM199602013340503
   PubMed Web of Science ®Google Scholar
• Kim WJ, Park CY. 1,5-Anhydroglucitol in diabetes mellitus. Endocrine. 2013;43(1):33–40. doi:10.1007/s12020-012-9760-6
   PubMedGoogle Scholar
• Loomis SJ, Kottgen A, Li M, et al. Rare variants in SLC5A10 are associated with serum 1,5-anhydroglucitol (1,5-AG) in the Atherosclerosis Risk in Communities (ARIC) Study. Sci Rep. 2019;9(1):5941. doi:10.1038/s41598-019-42202-0
   PubMedGoogle Scholar
• Kim WJ, Park CY, Lee KB, et al. Serum 1,5-anhydroglucitol concentrations are a reliable index of glycemic control in type 2 diabetes with mild or moderate renal dysfunction. Diabetes Care. 2012;35(2):281–286. doi:10.2337/dc11-1462
   PubMedGoogle Scholar
• Pal A, Farmer AJ, Dudley C, et al. Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes. Diabetes Care. 2010;33(2):252–257. doi:10.2337/dc09-1246
   PubMedGoogle Scholar
• Januszewski AS, Karschimkus C, Davis KE, O’Neal D, Ward G, Jenkins AJ. Plasma 1,5 anhydroglucitol levels, a measure of short-term glycaemia: assay assessment and lower levels in diabetic vs. non-diabetic subjects. 08B92. 2012;95(1):e17–19. doi:10.1016/j.diabres.2011.09.032
   Google Scholar
• Whitehead TP, Jungner I, Robinson D, Kolar W, Pearl A, Hale A. Serum urate, serum glucose and diabetes. Ann Clin Biochem. 1992;29(2):159–161. doi:10.1177/000456329202900206
   PubMedGoogle Scholar
• Mook-Kanamori DO, Selim MM, Takiddin AH, et al. 1,5-Anhydroglucitol in saliva is a noninvasive marker of short-term glycemic control. J Clin Endocrinol Metab. 2014;99(3):E479–483. doi:10.1210/jc.2013-3596
   PubMed Web of Science ®Google Scholar
• Selvin E, Rawlings AM, Grams M, Klein R, Steffes M, Coresh J. Association of 1,5-anhydroglucitol with diabetes and microvascular conditions. Clin Chem. 2014;60(11):1409–1418. doi:10.1373/clinchem.2014.229427
   PubMedGoogle Scholar
• Dungan KM, Buse JB, Largay J, et al. 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care. 2006;29(6):1214–1219. doi:10.2337/dc06-1910
   PubMedGoogle Scholar
• Bai Y, Yang R, Song Y, Wang Y. Serum 1,5-Anhydroglucitol concentrations remain valid as a glycemic control marker in diabetes with earlier chronic kidney disease stages. Exp Clin Endocrinol Diabetes. 2019;127(4):220–225. doi:10.1055/s-0043-122142
   PubMedGoogle Scholar
• Barnes VM, Kennedy AD, Panagakos F, et al. Global metabolomic analysis of human saliva and plasma from healthy and diabetic subjects, with and without periodontal disease. PLoS One. 2014;9(8):e105181. doi:10.1371/journal.pone.0105181
   PubMed Web of Science ®Google Scholar
• Asha ML, Rajarathnam BN, Vinutha N, Kumar HM, Premkumar A, Azmi R. Evaluation of 1, 5-anhydroglucitolas a salivary biomarker in Type 2 diabetes mellitus patients. J Adv Clin Res Insights. 2019;6(3):67–71. doi:10.15713/ins.jcri.263
   Google Scholar
• Ruge T, Lockton JA, Renstrom F, et al. Acute hyperinsulinemia raises plasma interleukin-6 in both nondiabetic and type 2 diabetes mellitus subjects, and this effect is inversely associated with body mass index. Metabolism. 2009;58(6):860–866. doi:10.1016/j.metabol.2009.02.010
   PubMedGoogle Scholar
• Rodrigues KF, Pietrani NT, Bosco AA, Campos FMF, Sandrim VC, Gomes KB. IL-6, TNF-alpha, and IL-10 levels/polymorphisms and their association with type 2 diabetes mellitus and obesity in Brazilian individuals. Arch Endocrinol Metab. 2017;61(5):438–446. doi:10.1590/2359-3997000000254
   PubMed Web of Science ®Google Scholar
• Castaneda S, Remuzgo-Martinez S, Lopez-Mejias R, et al. Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis. Clin Exp Rheumatol. 2019;37(3):465–473.
   PubMedGoogle Scholar
• Harder-Lauridsen NM, Krogh-Madsen R, Holst JJ, et al. Effect of IL-6 on the insulin sensitivity in patients with type 2 diabetes. Am J Physiol Endocrinol Metab. 2014;306(7):E769–778. doi:10.1152/ajpendo.00571.2013
   PubMedGoogle Scholar
• Lei CT, Su H, Ye C, et al. The classic signalling and trans-signalling of interleukin-6 are both injurious in podocyte under high glucose exposure. J Cell Mol Med. 2018;22(1):251–260. doi:10.1111/jcmm.13314
   PubMedGoogle Scholar
• Russo GT, Giorda CB, Cercone S, et al. Factors associated with beta-cell dysfunction in type 2 diabetes: the BETADECLINE study. PLoS One. 2014;9(10):e109702. doi:10.1371/journal.pone.0109702
   PubMed Web of Science ®Google Scholar
• Reeh H, Rudolph N, Billing U, et al. Response to IL-6 trans- and IL-6 classic signalling is determined by the ratio of the IL-6 receptor alpha to gp130 expression: fusing experimental insights and dynamic modelling. Cell Commun Signal. 2019;17(1):46. doi:10.1186/s12964-019-0356-0
   PubMedGoogle Scholar
• Vinagre I, Sanchez-Quesada JL, Sanchez-Hernandez J, et al. Inflammatory biomarkers in type 2 diabetic patients: effect of glycemic control and impact of LDL subfraction phenotype. Cardiovasc Diabetol. 2014;13:34. doi:10.1186/1475-2840-13-34
   PubMed Web of Science ®Google Scholar
• Pan A, Wang Y, Yuan JM, Koh WP. High-sensitive C-reactive protein and risk of incident type 2 diabetes: a case-control study nested within the Singapore Chinese Health Study. BMC Endocr Disord. 2017;17(1):8. doi:10.1186/s12902-017-0159-5
   PubMedGoogle Scholar
• Effoe VS, Correa A, Chen H, Lacy ME, Bertoni AG. High-sensitivity C-reactive protein is associated with incident type 2 diabetes among African Americans: the Jackson Heart Study. Diabetes Care. 2015;38(9):1694–1700. doi:10.2337/dc15-0221
   PubMed Web of Science ®Google Scholar
• Aryan Z, Ghajar A, Faghihi-Kashani S, Afarideh M, Nakhjavani M, Esteghamati A. Baseline high-sensitivity C-reactive protein predicts macrovascular and microvascular complications of type 2 diabetes: a population-based study. Ann Nutr Metab. 2018;72(4):287–295. doi:10.1159/000488537
   PubMedGoogle Scholar
• Asemi Z, Zare Z, Shakeri H, Sabihi SS, Esmaillzadeh A. Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in patients with type 2 diabetes. Ann Nutr Metab. 2013;63(1–2):1–9. doi:10.1159/000349922
   PubMed Web of Science ®Google Scholar
• Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med. 2012;18(3):363–374. doi:10.1038/nm.2627
   PubMed Web of Science ®Google Scholar
• Hanyu O, Yoshida J, Abe E, et al. High-sensitivity CRP reflects insulin resistance in smokers. J Atheroscler Thromb. 2009;16(5):560–567. doi:10.5551/jat.869
   PubMedGoogle Scholar
• Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes. 2004;53(3):693–700. doi:10.2337/diabetes.53.3.693
   PubMed Web of Science ®Google Scholar
• Redman RS, Kerr GS, Payne JB, et al. Salivary and serum procalcitonin and C-reactive protein as biomarkers of periodontitis in United States veterans with osteoarthritis or rheumatoid arthritis. Biotech Histochem. 2016;91(2):77–85. doi:10.3109/10520295.2015.1082625
   PubMed Web of Science ®Google Scholar
• Desai GS, Mathews ST. Saliva as a non-invasive diagnostic tool for inflammation and insulin-resistance. World J Diabetes. 2014;5(6):730–738. doi:10.4239/wjd.v5.i6.730
   PubMedGoogle Scholar
• Naidoo T, Konkol K, Biccard B, Dudose K, McKune AJ. Elevated salivary C-reactive protein predicted by low cardio-respiratory fitness and being overweight in African children. Cardiovasc J Afr. 2012;23(9):501–506. doi:10.5830/CVJA-2012-058
   PubMedGoogle Scholar
• Virkamaki A, Ueki K, Kahn CR. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest. 1999;103(7):931–943. doi:10.1172/JCI6609
   PubMed Web of Science ®Google Scholar
• Navarro JF, Mora C, Muros M, Garcia J. Urinary tumour necrosis factor-alpha excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients. Nephrol Dial Transplant. 2006;21(12):3428–3434. doi:10.1093/ndt/gfl469
   PubMed Web of Science ®Google Scholar
• Lainampetch J, Panprathip P, Phosat C, et al. Association of tumor necrosis factor alpha, interleukin 6, and C-reactive protein with the risk of developing type 2 diabetes: a retrospective cohort study of rural Thais. J Diabetes Res. 2019;2019:9051929. doi:10.1155/2019/9051929
   PubMed Web of Science ®Google Scholar
• Woo YC, Tso AW, Xu A, et al. Combined use of serum adiponectin and tumor necrosis factor-alpha receptor 2 levels was comparable to 2-hour post-load glucose in diabetes prediction. PLoS One. 2012;7(5):e36868. doi:10.1371/journal.pone.0036868
   PubMedGoogle Scholar
• Iwamoto Y, Nishimura F, Nakagawa M, et al. The effect of antimicrobial periodontal treatment on circulating tumor necrosis factor-alpha and glycated hemoglobin level in patients with type 2 diabetes. J Periodontol. 2001;72(6):774–778. doi:10.1902/jop.2001.72.6.774
   PubMed Web of Science ®Google Scholar
• Stephens JM, Pekala PH. Transcriptional repression of the GLUT4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. J Biol Chem. 1991;266(32):21839–21845.
   PubMedGoogle Scholar
• Abel ED, Peroni O, Kim JK, et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature. 2001;409(6821):729–733. doi:10.1038/35055575
   PubMed Web of Science ®Google Scholar
• Li JY, Wang YD, Qi XY, et al. Serum CCN3 levels are increased in type 2 diabetes mellitus and associated with obesity, insulin resistance and inflammation. Clin Chim Acta. 2019;494:52–57. doi:10.1016/j.cca.2019.03.006
   PubMed Web of Science ®Google Scholar
• Srinivasan M, Meadows ML, Maxwell L. Assessment of salivary adipokines resistin, visfatin, and ghrelin as type 2 diabetes mellitus biomarkers. Biochem Res Int. 2018;2018:7463796. doi:10.1155/2018/7463796
   PubMed Web of Science ®Google Scholar
• Gaman MA, Epingeac ME, Diaconu CC, Gaman AM. Evaluation of oxidative stress levels in obesity and diabetes by the free oxygen radical test and free oxygen radical defence assays and correlations with anthropometric and laboratory parameters. World J Diabetes. 2020;11(5):193–201. doi:10.4239/wjd.v11.i5.193
   PubMed Web of Science ®Google Scholar
• Epingeac ME, Gaman MA, Diaconu CC, Gad M, Gaman AM. The evaluation of oxidative stress levels in obesity. Rev Chim (Bucharest). 2019;70:2241–2244. doi:10.37358/RC.19.6.7314
   Web of Science ®Google Scholar
• Malamud D. Saliva as a diagnostic fluid. Dent Clin North Am. 2011;55(1):159–178. doi:10.1016/j.cden.2010.08.004
   PubMedGoogle Scholar
• Roi A, Rusu LC, Roi CI, Luca RE, Boia S, Munteanu RI. A new approach for the diagnosis of systemic and oral diseases based on salivary biomolecules. Dis Markers. 2019;2019:8761860. doi:10.1155/2019/8761860
   PubMed Web of Science ®Google Scholar